Pharmacology Biochemistry and Behavior 1988-11-01

Toxicity study of continuous administration of physostigmine salicylate.

D K Lim, Y Ito, T Stewart, B Hoskins, I K Ho

Index: Pharmacol. Biochem. Behav. 31(3) , 627-31, (1988)

Full Text: HTML

Abstract

The present study demonstrates that continuous administration with physostigmine salicylate (0.12 or 0.24 mg/kg/hr via mini-osmotic pumps) induces toxicities (e.g., body weight loss, decreased water consumption, tremors, decreased body temperatures, mortality) in guinea pigs. Both blood and brain cholinesterase activity is inhibited dose-dependently by physostigmine salicylate. The signs of toxicity in the guinea pigs which received the low dose appeared within 2 or 3 days and then the animals recovered, while toxic signs in the guinea pigs treated with the high dose of the drug persisted throughout the experiments. The study further shows that continuous administration of physostigmine salicylate also caused down-regulation of muscarinic receptors in the striata of the guinea pigs.


Related Compounds

Related Articles:

Possible interaction of cholinergic and GABAergic systems between MS and CA1 upon memory acquisition in rats.

2012-12-01

[Behav. Brain Res. 235(2) , 231-43, (2012)]

The effects of physostigmine infusion on patients with panic disorder.

1991-04-01

[Biol. Psychiatry 29(7) , 658-64, (1991)]

Development and optimization of a sublingual tablet formulation for physostigmine salicylate.

2009-09-01

[Acta. Pharm. 59(3) , 301-12, (2009)]

Liquid chromatographic analysis of physostigmine salicylate and its degradation products.

1999-01-01

[J. Pharm. Biomed. Anal. 18(6) , 939-45, (1999)]

Brain neurotransmitter systems mediating behavioral deficits produced by inescapable shock treatment in rats.

1988-04-26

[Brain Res. 447(1) , 122-32, (1988)]

More Articles...